Vanda

Discussion in 'Vanda Pharmaceuticals' started by anonymous, Dec 7, 2016 at 2:43 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Silly Rabbit. You must be an outsider. Such mundane and inconsequential details like intakes actually being intakes or patients treated equaling patients triaged or, you know, having PROOF supporting your claim that H treats insomnia or sighted patients are things you don’t need to concern yourself with. Heck, certain territories are killing it with H “intakes”. Do the details really matter?

    Stock is up. Go back to work or I’ll purge more older, inflexible, conscientious-ethical reps.
     

  2. anonymous

    anonymous Guest

    and what percentage of "intakes" actually result in medication being dispensed to a patient?
    How could Vanda recognize revenue on intakes? are they shipping to a wholesaler or specialty pharmacy on intake and then either taking the medication back or writing it off if not dispensed? I'm trying to complete the loop here. many thanks!
     
  3. anonymous

    anonymous Guest

    And let's not forget the numerous price increases since launch. By my estimation, Hetlioz is almost 200% more expensive than when it launched. And yet when asked on the last analyst call, the chief number-massager tapped danced all around giving an answer. It's a simple question - what percentage of patients triaged actually get medication? But the stock is up based largely on very, VERY, fuzzy math. Sarbanes-Oxley anyone?
    And the reps are incentivized to generate intakes by whatever means necessary.

    This place is Purdue and Enron all mixed together.

    Welcome to Pur-vanda-ron!
     
  4. anonymous

    anonymous Guest

    highlights from poly presentation at cantor (available on IR page):
    1. only a "small portion" of patients get hetlioz rx filled. poly blamed insurers.
    2. Poly had the audacity to say he is very sensitive to making sure drugs are affordable. (the wall street analyst announced with admiration that poly has "always been very thoughtful about pharmacoeconomics.")
    3. the reason they did the driving impairment study was to attract insomnia patients away from ambien and lunesta.
    4. since initiating the hetlioz to psych strategy, monthly DEMAND for hetlioz has "tripled." (We can debate the tripling, but love his choice of words. "demand." he readily admits only a "small portion" of patients ever get filled.)

    I would be happy to introduce Poly to dozens of patients who would disagree that Hetlioz was priced affordably. and who never got their Rx filled. does this guy spend any time talking to sales or patient community?

    still puzzling how they are able to turn "demand" (that never gets filled) into sales revenue. There must be someone who can explain this.
     
  5. anonymous

    anonymous Guest

    Poly's defense attorney will explain it at his trial.
    That is too funny. Affordable medication?!?!. There is absolutely no reason whatsoever that Hetlioz is not sampled and available at CVS. Poly is simply greedy. His cold heart does not care about patients.
    So, he's saying the trial makes it ok to talk about insomnia and superiority over Ambien and Lunesta?? I already know the answer: of course not, wink wink come on sales team, time to talk off label even more.
    Purdue and Enron weren't nearly as poorly and criminally run than Vanda.
     
  6. anonymous

    anonymous Guest

    Poly blames insurers. That's funny. Maybe Poly needs to buy a mirror to see who is to blame. It's MELATONIN. It should not cost nearly $200K per year. And there is no reason for an issuer to pay for it in a sighted patient. Greedy Poly had a drug for blind patients with non 24 but has exposed himself for the fraud he is by pushing it for insomnia. Crooked Vanda
     
  7. anonymous

    anonymous Guest

    I received an interesting call about Vanda. Looks like the Feds are investigating this scum bag of a company.
     
  8. anonymous

    anonymous Guest

    Not much of a surprise considering the dictator running the company has little concern for the law.
     
  9. anonymous

    anonymous Guest

    I call bullshit.
     
  10. anonymous

    anonymous Guest

    It's not bs when multiple people are receiving such calls (and I wish that they would call me)!
     
  11. anonymous

    anonymous Guest

    Nope its happening to current AND former employees.
     
  12. anonymous

    anonymous Guest

    straight from the Vanda SEC filings:
    "Third-party payors are increasingly challenging the prices charged for medical products and services. It will be time consuming and expensive for us or our partners to go through the process of seeking reimbursement from Medicare and private payors. Our products may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us or our partners to sell our compounds on a competitive and profitable basis."
    emphasis is mine.
    great statement directly from the company. And then dr poly has the stones to go to wall street and blame the insurers and say he is very careful and thoughtful about pricing and affordability.
     
  13. anonymous

    anonymous Guest

    He is and has always been a liar and a fraud.
     
  14. anonymous

    anonymous Guest

    So here is a post in September about our stock and this is an explanation of what we do. Look at it and tell me what is wrong with this picture
     
  15. anonymous

    anonymous Guest

     
  16. anonymous

    anonymous Guest

    Vanda Pharma Treatments
    Vanda develops treatments for insomnia, schizophrenia, depression and other central nervous system disorders. The biotech stock expects full-year 2018 net sales of its drug Hetlioz, which treats non-24-hour sleep-wake disorder, to reach $108 million to $118 million. That's up from net sales totaling $13 million in 2014, when Hetlioz launched.

    The new S&P 600 member also has conducted clinical studies for the drug to treat jet lag disorder as well as Smith-Magenis Syndrome.

    Its schizophrenia treatment Fanapt is expected to generate net sales of $72 million to $82 million in 2018, according to the company.
     
  17. anonymous

    anonymous Guest


    Insomnia??

    Depression??

    What's the name of those medications?
     
  18. anonymous

    anonymous Guest

    Well they are even telling investors they want to sell off label wow! Talk about proof for the FDA.!
     
  19. anonymous

    anonymous Guest

    Hmmm. developing a drug for depression?? Hey Poly, you haven't conducted one single depression trial in the 9 years that Fanapt has been on the market. Why are you continuing to lie to investors? That is a crime, you know.

    Insomnia? Well reps are commanded to sell Hetlioz for insomnia or be purged. Where is that insomnia data in the label? Is it right there with the data that doesnt exist for using Hetlioz in sighted patients?

    TGIF, I can wash the Vanda stink off of me for a couple of days.
     
  20. anonymous

    anonymous Guest

    Yep and as reps we can’t even get paid on Hetlioz , somehow they get out of paying you every quarter that is why sales keeps going up because they demand the sales but yet will not pay for getting the 118 million we have made you. The account managers have more and more each quarter and the Fanapt sales force is selling the crap out of Hetlioz or some are if they are selling off label haha but they don’t value the sales force because we are not the ones selling this overpriced medicine it is all Poly doing it right . Haha.